These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 18854763

  • 21. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 22. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 27; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 23. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
    Fernández A, Marcén R, Pascual J, Galeano C, Ocaña J, Arellano EM, Alfaro C, Villafruela JJ, Burgos FJ, Ortuño J.
    Transplant Proc; 2006 Oct 27; 38(8):2453-5. PubMed ID: 17097965
    [Abstract] [Full Text] [Related]

  • 24. Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach.
    Sumethkul V, Tankee P, Chalermsanyakorn P, Jirasiritham S.
    Transplant Proc; 2010 Dec 27; 42(10):4040-2. PubMed ID: 21168621
    [Abstract] [Full Text] [Related]

  • 25. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 26. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.
    Piao SG, Bae SK, Lim SW, Song JH, Chung BH, Choi BS, Yang CW.
    Transplantation; 2012 Feb 27; 93(4):383-9. PubMed ID: 22267156
    [Abstract] [Full Text] [Related]

  • 27. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
    Andrés V, Castro C, Campistol JM.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii14-7. PubMed ID: 16815851
    [Abstract] [Full Text] [Related]

  • 28. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
    Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM, Everolimus Pediatric Study Group.
    Pediatr Transplant; 2008 Jun 27; 12(4):456-63. PubMed ID: 18466433
    [Abstract] [Full Text] [Related]

  • 29. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A.
    Pape L, Ahlenstiel T, Ehrich JH, Offner G.
    Pediatr Transplant; 2007 May 27; 11(3):291-5. PubMed ID: 17430485
    [Abstract] [Full Text] [Related]

  • 30. Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference.
    Hummel M.
    J Heart Lung Transplant; 2005 Apr 27; 24(4 Suppl):S196-200; discussion S210-1. PubMed ID: 15774322
    [Abstract] [Full Text] [Related]

  • 31. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
    Havenith SH, Yong SL, van Donselaar-van der Pant KA, van Lier RA, ten Berge IJ, Bemelman FJ.
    Transplantation; 2013 Jan 15; 95(1):184-91. PubMed ID: 23222818
    [Abstract] [Full Text] [Related]

  • 32. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
    Sommerer C, Schnitzler P, Meuer S, Zeier M, Giese T.
    Ther Drug Monit; 2011 Dec 15; 33(6):694-8. PubMed ID: 22105585
    [Abstract] [Full Text] [Related]

  • 33. Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo.
    Jespersen B, Thiesson HC, Henriksen C, Therland K, Falk C, Poulsen T, Fogh B, Madsen K, Walther S, Jensen BL.
    Nephrol Dial Transplant; 2009 May 15; 24(5):1644-55. PubMed ID: 19193738
    [Abstract] [Full Text] [Related]

  • 34. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec 15; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 35. Sirolimus in renal transplantation.
    Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, Zeier M.
    Nephrol Dial Transplant; 2007 Sep 15; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [Abstract] [Full Text] [Related]

  • 36. Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: an echocardiographic substudy of the randomized controlled CENTRAL trial.
    Murbraech K, Holdaas H, Massey R, Undset LH, Aakhus S.
    Transplantation; 2014 Jan 27; 97(2):184-8. PubMed ID: 24092385
    [Abstract] [Full Text] [Related]

  • 37. Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy.
    Ma X, Lu YP, Yang L, Song J, Luo GH, Shi YJ, Li YP.
    Transplant Proc; 2008 Oct 27; 40(8):2804-7. PubMed ID: 18929866
    [Abstract] [Full Text] [Related]

  • 38. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
    Böhler T, Waiser J, Lichter S, Schumann B, Neumayer HH, Kamar N, Budde K.
    Cytokine; 2008 Jun 27; 42(3):306-11. PubMed ID: 18440821
    [Abstract] [Full Text] [Related]

  • 39. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function.
    Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A, Begliomini B, Di Benedetto F, Gerunda GE.
    Am J Transplant; 2010 Oct 27; 10(10):2252-62. PubMed ID: 20486905
    [Abstract] [Full Text] [Related]

  • 40. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
    Li JT, Danguilan RA, Cabanayan-Casasola CB, Talusan-Tomacruz Y, Ona ET.
    Transplant Proc; 2008 Sep 27; 40(7):2211-3. PubMed ID: 18790195
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.